UNUSUAL VOLUME AND PRICE ACTIVITY IN TRACON PHARMA

KEEP ON STRONG WATCH FOR A BREAKOUT ON CONTINUATION AFTER A SEVERAL STRONG TRADING SESSIONS. ALERT SET FOR BREAK OF $.91 FOR PROJECTED TARGET OF $1.30. SPECULATIVE AND RISKY.

AVERAGE ANALYSTS PRICE TARGET $1.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT

COMPANY PROFILE
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.